- PR Newswire•13 days ago
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that its Chief Executive Officer, Philip Serlin, and its Chief Business Officer, David Malek, will present a company update at the 2016 BIO CEO & Investor Conference on Tuesday, February 14, 2017 at 10:30 am EST. The conference will be held at the Waldorf Astoria Hotel in New York. A live webcast of the presentation will be available on BioLineRx's website.
- Zacks•last month
BioLineRx (BLRX) announced the initiation of a second phase IIa study on BL-8040 in combination with Keytruda for the treatment of pancreatic cancer.
- PR Newswire•last monthBioLineRx Announces Initiation of Immuno-Oncology Phase 2 Study to Investigate Combination of BL-8040 and KEYTRUDA® for Pancreatic Cancer
TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today the initiation of a second Phase 2a trial investigating BL-8040 in combination with KEYTRUDA® (pembrolizumab), MSD's anti-PD-1 therapy, in patients with metastatic pancreatic cancer. The study is part of a research collaboration between MSD and MD Anderson Cancer Center. The open-label, single center, single-arm Phase 2a study aims to evaluate the potential of BL-8040 in combination with KEYTRUDA in pancreatic cancer and focuses on the mechanism-of-action by which both drugs might synergize.
BLRX : Summary for BioLineRx Ltd. - Yahoo Finance
BioLine Rx Ltd (BLRX)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
|Bid||1.27 x 500|
|Ask||1.32 x 12300|
|Day's Range||1.20 - 1.35|
|52 Week Range||0.83 - 1.42|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-4.62|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|